Post-Infusion CAR T_Reg Cells Identify Patients Resistant to CD19-CAR Therapy

Single-cell proteomic profiling of circulating CAR T cells in 32 patients treated with CD19-CAR identified that CD4+Helios+ CAR T cells on day seven after infusion were associated with progressive disease and less severe neurotoxicity.